Overview

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Pierrel Research Europe GmbH
Collaborator:
Roche Pharma AG
Treatments:
Ganciclovir
Ganciclovir triphosphate
Valganciclovir